Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7895656 | 1.00 | ALOX5 (0.53) | ALOX5PIK3CDFAAHMGLLADRA1B | |
| SCHEMBL297237 | 1.00 | ALOX5 (0.53) | ALOX5PIK3CDFAAHMGLLADRA1B | |
| SCHEMBL707139 | 1.00 | ALOX5 (0.53) | ALOX5PIK3CDFAAHMGLLADRA1B | |
| SCHEMBL297935 | 1.00 | ALOX5 (0.53) | ALOX5PIK3CDFAAHMGLLADRA1B | |
| SCHEMBL430004 | 1.00 | ALOX5 (0.53) | ALOX5PIK3CDFAAHMGLLADRA1B | |
| SCHEMBL297738 | 1.00 | ALOX5 (0.53) | ALOX5PIK3CDFAAHMGLLADRA1B | |
| SCHEMBL6575811 | 1.00 | ALOX5 (0.53) | ALOX5PIK3CDFAAHMGLLADRA1B | |
| SCHEMBL37427 | 1.00 | ALOX5 (0.53) | ALOX5PIK3CDFAAHMGLLADRA1B | |
| SCHEMBL6012088 | 1.00 | ALOX5 (0.53) | ALOX5PIK3CDFAAHMGLLADRA1B | |
| SCHEMBL31601999 | 1.00 | ALOX5 (0.53) | ALOX5PIK3CDFAAHMGLLADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113365696-A | Pharmaceutical compounds and their use as inhibitors of ubiquitin-specific protease 19(USP19) | 阿尔麦克探索有限公司 | 2021-09-07 | — | — | CN | claimed |
| CN-112135818-A | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin-specific protease 19(USP19) | 阿尔麦克探索有限公司 | 2020-12-25 | — | — | CN | claimed |
| EP-3434269-B1 | TRANSDERMAL ABSORPTION-TYPE PATCH PREPARATION COMPRISING ZONISAMIDE | TEIKOKU SEIYAKU KK (JP) | 2020-12-23 | — | — | EP | claimed |
| US-20190070122-A1 | TRANSDERMAL ABSORPTION-TYPE PATCH PREPARATION COMPRISING ZONISAMIDE | TEIKOKU SEIYAKU CO., LTD. (JP) | 2019-03-07 | — | — | US | claimed |
| EP-3434269-A1 | TRANSDERMAL ABSORPTION-TYPE PATCH PREPARATION COMPRISING ZONISAMIDE | Teikoku Seiyaku Co., Ltd. (JP) | 2019-01-30 | — | — | EP | claimed |
| CN-108883097-A | Percutaneous patch containing Zonisamide | 帝国制药株式会社 | 2018-11-23 | — | — | CN | claimed |
| CN-120065654-A | Aqueous developer composition for flexographic printing plate and method for producing flexographic printing plate | 旭化成株式会社 | 2025-05-30 | — | — | CN | disclosed |
| US-20230157284-A1 | HIGH-LOAD SOLUTION CONCENTRATES OF DICAMBA | BASF CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230148590-A1 | Aqueous Formulations of Dicamba | BASF CORPORATION | 2023-05-18 | — | — | US | disclosed |
| EP-4132274-A1 | HIGH-LOAD SOLUTION CONCENTRATES OF DICAMBA | BASF Corporation (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-4125365-A1 | AQUEOUS FORMULATIONS OF DICAMBA | BASF Corporation (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115361868-A | High-load solution concentrates of dicamba | 巴斯夫公司 | 2022-11-18 | — | — | CN | disclosed |
| WO-2021198458-A1 | AQUEOUS FORMULATIONS OF DICAMBA | BASF CORPORATION (US) | 2021-10-07 | — | — | WO | disclosed |
| CN-1424626-A | Forming method for photoresist design and its laminating products | TOKYO OKA GOGYO K K (JP) | 2003-06-18 | — | — | CN | disclosed |
| US-20030053964-A1 | Process for the preparation of hydroxybenzoic benzyl esters | BAYER AKTIENGESELLSCHAFT (DE) | 2003-03-20 | — | — | US | disclosed |
| EP-1249443-A2 | Process for the production of hydroxybenzoic acid benzyl esters | BAYER AG (DE) | 2002-10-16 | — | — | EP | disclosed |
| US-20010021489-A1 | Photoresist stripping solution and a method of stripping photoresists using the same | TOKYO OHKA KOGYO CO., LTD. (JP) | 2001-09-13 | — | — | US | disclosed |
| US-6132928-A | Coating solution for forming antireflective coating film | TOKYO OHKA KOGYO CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| US-5783362-A | Liquid coating composition for use in forming photoresist coating films and a photoresist material using said composition | TOKYO OHKA KOGYO CO., LTD. (JP) | 1998-07-21 | — | — | US | disclosed |
| US-5631314-A | Liquid coating composition for use in forming photoresist coating films and photoresist material using said composition | TOKYO OHKA KOGYO CO., LTD. (JP) | 1997-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148590-A1 | Aqueous Formulations of Dicamba | BOLA2; BOLA2B, CIP2A, AQP1 | ALOX5 1433/4885PIK3CD 1042/4885FAAH 3379/4885 |
| US-20230157284-A1 | HIGH-LOAD SOLUTION CONCENTRATES OF DICAMBA | PDHB, PDHA1, LDHB | ALOX5 739/4885PIK3CD 316/4885FAAH 4037/4885 |
| US-20030053964-A1 | Process for the preparation of hydroxybenzoic benzyl esters | HAAO, HPD, HACL2 | ALOX5 232/4885PIK3CD 2608/4885FAAH 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.